Zimmer Biomet

“given Johnson & Johnson's announcement, a long-duration exit tends to throw up opportunities for others.”

An analyst frames Johnson & Johnson's orthopedics exit as a share opportunity for competitors like Zimmer Biomet; management acknowledges spin-off disruption.

“guidance excludes the impact from the Paragon 28 acquisition that closed in April.”

Zimmer Biomet's Paragon 28 foot-and-ankle acquisition (closed April 2025) is integrating well and growing double digits organically.

“on October 7, we closed the acquisition of Monogram Technologies, which is the company behind the mBôs, semi and fully autonomous AI-driven, orthopedic robotic system.”

Zimmer Biomet closed its acquisition of Monogram Technologies, adding semi- and fully-autonomous orthopedic surgical robotics to its portfolio.

“We just extended the exclusive partnership with THINK Surgical.”

Zimmer Biomet extended its exclusive robotics partnership with THINK Surgical for a smaller handheld CT-based platform, with a sizable deal pipeline building.

“Stryker and Mako will get a lot of credit for being visionaries 10 years ago and changing how orthopedics get done.”

Zimmer's CEO credits Stryker's Mako robot as the visionary first mover in orthopedic robotics, framing Stryker as the incumbent leader Zimmer aims to leapfrog with autonomous robotics.

“The acquisition of Paragon 28 earlier this year is another way we're leveraging M&A to diversify our company into higher growth segments.”

Zimmer Biomet completed its acquisition of foot-and-ankle specialist Paragon 28, integrating its commercial channel and expecting 270 bps of 2025 growth contribution.

“On July 14, we announced a definitive agreement to acquire Monogram Technologies, which is the company behind mBôs, the robot with semi and fully autonomous AI-driven robotic capabilities.”

Zimmer Biomet agreed to acquire Monogram Technologies for its autonomous surgical robot, a read-through validating Monogram's mBôs platform as disruptive orthopedic technology.

“it's Stryker's recon growth, particularly its U.S. Knee growth, continues to be a lot higher than the other three competitors and we can all see that obviously. We did a lot of channel checks around AAOS, and we continue to hear that the difference is really just still Mako (ph).”

An analyst cites Stryker's faster U.S. Knee growth relative to Zimmer Biomet and other competitors, attributing the gap to Stryker's Mako robotic platform.

“CBRE comes to mind. Already signed up a deal with CBRE in that space.”

Zimmer Biomet cites a signed partnership with CBRE supporting its push into the ambulatory surgical center (ASC) space.

“To complement our product cycle on January 28th, we entered into a definitive agreement to acquire Paragon 28, which is a leader in the rapidly growing $5 billion foot and ankle space.”

Zimmer Biomet announced a definitive agreement to acquire Paragon 28 for an upfront $1.1 billion equity purchase price, adding a foot-and-ankle leader to its portfolio.